Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Cell Cycle Regulation Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CDKN2B drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CDKN2B Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Ideal for CDK4/6 binding studies. |
View CDKN2B Products |
| Gene Delivery | CDKN2B Promise-ORF / Lentivirus Full-length ORF for stable cell lines and overexpression validation. |
View CDKN2B Products |
| Benchmark Ab | Anti-CDKN2B Recombinant Antibody High-affinity positive control for IHC, WB, and ELISA validation. |
View CDKN2B Products |
| Validator | CDKN2B siRNA Set For knockdown verification in target-specificity assays. |
View CDKN2B Products |
| Related Target A | CDK4 Direct downstream kinase partner inhibited by CDKN2B; crucial for cell cycle G1/S checkpoint assays. |
View CDK4 Products |
| Related Target B | CDK6 Synergistic cell-cycle driver; key target for evaluating CDKN2B-mimetic specificity. |
View CDK6 Products |
| Related Target C | MTAP Co-deleted with CDKN2A/B in many cancers; primary target for synthetic lethality screening. |
View MTAP Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Protein Stability & Conformation | Eukaryotic (HEK293) and prokaryotic expression systems optimized for native fold and stability. |
| Subfamily Off-target Screening | Homolog panels (CDKN2A/p16, CDKN2C/p18, CDKN2D/p19) strictly verified by mass spectrometry. |
| Lack of Validated Controls | Sequence-verified clinical-grade benchmark antibodies included in the portfolio. |
| False Positives in Phenotypic Screening | Sequence-specific siRNA sets included for target-specific knockdown validation. |
Live CDKN2B R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CDKN2B therapeutics is intensifying, with major players shifting focus from traditional small-molecule CDK4/6 inhibitors to targeted epigenetic reactivation, gene therapy restoration, and synthetic lethality profiling. As first-generation CDK4/6 inhibitors encounter clinical resistance, the next wave of R&D is targeting CDKN2B-deficient tumors, utilizing co-deletion markers such as MTAP to execute synthetic lethal strategies.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Gene Therapy / mRNA | Academic Institutes, Biotech Startups | Glioblastoma, Hematological Malignancies | Overexpression Validation (Need Lentivirus for Stable Cell Lines) |
| Epigenetic Reactivators (DNMTi/HDACi) | Merck, Bristol Myers Squibb | Myelodysplastic Syndromes, Solid Tumors | Expression Rescue Assays (Need High-specificity CDKN2B Antibodies) |
| Synthetic Lethal Small Mol (MAT2A/PRMT5) | Amgen, Agios Pharmaceuticals, Tangent | MTAP/CDKN2B Co-deleted Cancers | Selectivity Screening (Need Recombinant CDKN2B & MTAP Proteins) |